Related Experiment Video
Updated: Oct 2, 2025
06:09
An In Ovo Model for Testing Insulin-mimetic Compounds
Published on: April 23, 2018
10.8K
Exploring New Drug Targets for Type 2 Diabetes: Success, Challenges and Opportunities.
Abhinav Kanwal1, Navjot Kanwar2, Sanjay Bharati3
1Department of Pharmacology, All India Institute of Medical Sciences (AIIMS), Bathinda 151001, India.
Biomedicines
|February 25, 2022
Summary
Current type 2 diabetes mellitus treatments face significant challenges, including drug purity and toxicity concerns. Further research into novel mechanisms and target safety is crucial for developing improved diabetes medications.
Area of Science:
- Endocrinology and Metabolism
- Pharmacology and Pharmaceutical Sciences
- Drug Discovery and Development
Background:
- Substantial shortcomings persist in current type 2 diabetes mellitus (T2DM) pharmacotherapies, despite advancements.
- The global diabetes crisis remains unaddressed, highlighting unmet patient needs and the demand for novel therapeutic strategies.
- Recent concerns regarding the carcinogenic contaminant N-nitroso dimethylamine (NDMA) in metformin underscore purity and toxicity challenges in T2DM drug development.
Purpose of the Study:
- To review the current landscape of T2DM drug discovery, identifying persistent challenges and emerging issues.
- To emphasize the critical need for rigorous evaluation of drug purity, toxicity, and mechanistic characteristics.
- To guide future research towards identifying novel pharmacological molecules with enhanced selectivity and specificity for T2DM treatment.
Main Methods:
- Literature review of existing T2DM drugs and drug discovery trends.
- Analysis of recent challenges, including contaminant detection in widely used medications like metformin.
- Examination of newer drug classes (e.g., SGLT-2 inhibitors, GLP-1 receptor agonists, DPP-4 inhibitors) for progress and limitations.
Main Results:
- Despite market-driven advancements and a rise in new molecules, significant challenges in T2DM drug development persist.
- Purity and toxicity are major hurdles, exemplified by NDMA contamination in metformin.
- Newer drug classes show promise but also present difficulties, necessitating careful mechanistic and safety profiling.
Conclusions:
- The development of effective T2DM treatments requires addressing critical issues of drug purity, toxicity, and target safety.
- A deeper understanding of mechanistic characteristics and exposure-related hazards is essential for discovering safer and more effective pharmacological agents.
- Future drug discovery efforts must prioritize selectivity and specificity to meet unaddressed patient needs in T2DM management.
More Related Videos
Related Concept Videos
01:24Glucagon-like Receptor Agonists
457
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
457
01:26Drug Discovery: Overview
9.3K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
9.3K
01:15Diabetes: Management and Pharmacotherapy
427
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
427
01:22Diabetes Mellitus: Type 2 and Gestational
3.1K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
3.1K
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
328
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
328
01:36Carbohydrate Metabolism
12.2K
Carbohydrates are polymers composed of molecules containing atoms of carbon, hydrogen and oxygen. One gram of carbohydrate can provide four kilo-calories of energy, which makes it the most efficient instant energy source.
Starch accounts for approximately 60% of the carbohydrates consumed by humans. Since amylase enzymes cannot function in the stomach's acidic environment, starch can only be digested in the mouth and small intestine. Simple sugars are found naturally in milk and fruits in...
Starch accounts for approximately 60% of the carbohydrates consumed by humans. Since amylase enzymes cannot function in the stomach's acidic environment, starch can only be digested in the mouth and small intestine. Simple sugars are found naturally in milk and fruits in...
12.2K